As global biotech investment patterns shift, investors are turning their eyes to Asia-Pacific. While China remains a powerhouse, emerging hubs like Singapore and South Korea are quickly gaining attention for their political stability, strong IP protection, and innovation-friendly policies.
Why are APAC biotech markets suddenly so appealing to investors? And how are these emerging hubs reshaping the future of global biotech innovation?
On Wealth Tracker, Hongbin Jeong speaks to Fabio La Mola, Partner at Bain & Company, to find out more.

The Big Story: The end of cheap petrol? Malaysia’s RM1.99 RON95 under threat from the Iran conflict
13:54

Wealth Tracker: Why high-net-worth families should rethink wealth
17:19

What’s Trending: Is laughing while driving really dangerous? And could you recognise Barbies by touch?
17:09